Podcast: TRK fusion-positive GI cancers
Podcast: TRK fusion-positive GI cancers
Prof. Frédérique Penault-Llorca, Prof. Andrea Sartore-Bianchi
In this NTRK CONNECT podcast Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi discuss the detection and management of TRK fusion-positive GI cancers.
Prof. Frédérique Penault-Llorca
Pathologist
University of Clermont-Ferrand
France
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy
Podcast | 
20 min
|
Oct 2021
download resources
I agree that this educational programme:
In the GI episode, Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi provide a summary and share their personal experiences about the diagnosis and treatment of TRK fusion-positive GI cancer.
Prof Sartore-Bianchi provides an overview of NTRK genes and the biology of NTRK fusions, including their role as a driver of oncogenesis. He then provides a concise summary of the approved TRK inhibitor therapies, larotrectinib and entrectinib, emphasising the expanding dataset showing high response rates and durable responses seen in patients with GI cancers.
Prof Penault-Llorca outlines the challenges pathologists face detecting the extremely rare NTRK fusions in GI cancers, providing a summary of the range of tools available to detect them and offering her perspectives on an enrichment strategy for GI cancers, especially colorectal cancer.
They conclude by emphasising the importance of not missing any patients, through applying enrichment strategies that can enhance the likelihood of finding NTRK fusions. In doing so, more patients will be able to benefit from the proven efficacy of TRK inhibitor therapy.
Podcast Transcript
Frédérique Penault-Llorca
Today, with Andrea we are going to go through the diagnosis and treatment of NTRK fusion-positive GI cancers. Andrea, what are the NTRK genes, and what about the NTRK fusion; why are they so interesting to look at in GI cancers?
Andrea Sartore-Bianchi
Yes, thank you Frédérique, and indeed we know the gene fusions can be a driver of oncogenesis, but it is now when we are seeing very important advances in clinical sequencing technologies that we are aware of new…
This programme is supported by an Independent Educational Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
5 min
Other programmes developed by Prof. Frédérique Penault-Llorca
Prof. Frédérique Penault-Llorca
Pathologist
University of Clermont-Ferrand
France
Other programmes developed by Prof. Andrea Sartore-Bianchi
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy
